A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

I5Q-MC-CGAJ -

The main purpose of this study is to evaluate the longer term safety of the study drug known as LY2951742 in participants with episodic or chronic migraine.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Migraines
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
No
Enrollment Goal
270
Trial Dates
Nov 30, 2015 - Aug 14, 2018
How long will I be in the trial?
Your participation could last up to 16 months and include 17 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.